ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 764

The Impact of Adalimumab On Growth in Patients with Juvenile Idiopathic Arthritis

D. J. Lovell1, Nicolino Ruperto2, Katerina Jarosova3, Dana Nemcova4, Veronika Vargova3, Hartmut Michels3, Elizabeth Chalom5, Norman Ilowite5, Carine Wouters6, Hermine Brunner7, Karolyn Kracht8, Hartmut Kupper9, Edward Giannini5, Alberto Martini10 and Neelufar Mozaffarian11, 1Cincinnati Children's Hospital, Cincinnati, OH, 2Paediatric Rheumatology International Trials Organisation–IRCCS [PRINTO], Genova, Italy, 3PRINTO, Gaslini Institute, Genova, Italy, 4Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, 5PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 6PRINTO, Genoa, Italy, 7PRCSG, Cincinnati Children’s Hospital Medical Center, Genova, Italy, 8Abbott, Abbott, Abbott Park, IL, 9Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, 10Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, 11Abbott, Abbott Park, IL

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Adalimumab and juvenile arthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Pediatric Rheumatology: Clinical and Therapeutic Disease I: Juvenile Idiopathic Arthritis I

Session Type: Abstract Submissions (ACR)

 

Background/Purpose: Children with juvenile idiopathic arthritis (JIA) often exhibit growth impairments. Treatment with adalimumab (ADA) has been shown to be safe and effective in JIA patients (pts) when dosed every other week (eow) for up to 3 years,1 but the effect of ADA on growth is not known. The purpose of this post hoc analysis is to describe growth parameters in pts with JIA treated with ADA in a clinical trial setting.

Methods: Pts aged 4-17 with polyarticular course JIA were enrolled in a phase 3, randomized-withdrawal, double-blind (DB), stratified, parallel-group study, which consisted of a 16-wk open-label (OL) lead-in phase, a 32-wk DB phase, and an OL extension (OLE) phase. In the OLE phase, pts were dosed based on body surface area (24 mg/m2, max 40 mg dose), followed by a switch to 20 or 40 mg eow based on a body weight of ≤30 kg or >30 kg, respectively. To enter the DB phase, pts had to achieve an American College of Rheumatology Pediatric score ≥30% (ACR Pedi 30) during the OL lead-in. Pts could enter the OLE after 32 wks in the DB phase or at time of first flare (whichever came sooner). For this analysis, pts in the DB phase were grouped by baseline weight into 2 groups: ≤33rd percentile and >33rd percentile based on the US Centers for Disease Control and Prevention (CDC) growth charts. All pts who received ≥1 dose of ADA ± methotrexate (MTX) were included in the analysis. Mean CDC percentile changes in height, weight, and body mass index (BMI) percentiles were calculated through 104 weeks. Growth and efficacy data were analyzed using last observation carried forward (LOCF).

Results: Among the 171 pts enrolled in this study, 144 (84%) met ACR Pedi 30 response criteria at week 16, and 133 (78%) entered the DB phase. Of the 133 pts, 77% were female, with a mean age of 11.2 years, and a mean disease duration of 3.8 years; at baseline, 55 pts (41%) were in the ≤33rd percentile for weight and 78 pts (59%) were >33rd percentile. There were no differences between MTX and non-MTX groups in mean changes from baseline in weight, height, or BMI percentiles (P>.26). Pts in the lower 33rd percentile climbed to a higher mean growth rate through 104 weeks of ADA treatment (Figure). For those who started in the >33rd percentile, growth rates showed an initial increase that remained in the normal range throughout the study (Figure). Similar patterns were observed for height and BMI percentiles in these 2 groups. ACR Pedi 30/50/70/90 response rates improved over time in both groups, reaching 85%/76%/60%/36% for the ≤33rd percentile group and 83%/76%/51%/29% for the >33rd percentile group by the end of the DB phase with ADA treatment.

Conclusion: Long-term ADA treatment ± MTX is associated with improvement and maintenance of growth in children with JIA who had experienced impaired development. ADA treatment improved JIA signs and symptoms in both groups, regardless of baseline growth status.

Reference: 1Lovell DJ, et al. NEJM 2008;359:810-820.

 


Disclosure:

D. J. Lovell,
None;

N. Ruperto,
None;

K. Jarosova,
None;

D. Nemcova,
None;

V. Vargova,
None;

H. Michels,
None;

E. Chalom,
None;

N. Ilowite,
None;

C. Wouters,
None;

H. Brunner,
None;

K. Kracht,

Abbott Laboratories,

1,

Abbott Laboratories,

3;

H. Kupper,

Abbott Laboratories,

1,

Abbott Laboratories,

3;

E. Giannini,

Abbott Laboratories,

2;

A. Martini,
None;

N. Mozaffarian,

Abbott Laboratories,

1,

Abbott Laboratories,

3.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-adalimumab-on-growth-in-patients-with-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology